Last reviewed · How we verify

NCT04811417: Mar-Kid

Frailty Assessment Among Kidney Transplant Candidates

Completed Last updated 22 September 2021
What this trial tests

trial in Frailty in 500 participants. Completed in 30 June 2020.

Timeline
1 June 2015
Primary endpoint
30 June 2020
30 June 2020

Quick facts

Lead sponsorParc de Salut Mar
StatusCompleted
Study typeOBSERVATIONAL
Enrollment500
Start date1 June 2015
Primary completion30 June 2020
Estimated completion30 June 2020

Conditions studied

Sponsor

Parc de Salut Mar — full company profile →

Who can join

18 and older, any sex, with Frailty or Kidney Transplant; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Frailty is common among chronic kidney disease patients who are on the kidney transplant (KT) waiting list. The aim of this study is to assess frailty according to different frailty tools among KT candidates and to establish potential biomarkers of frailty.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Frailty and sarcopenia metabolomic signatures in kidney transplant candidates: the FRAILMar study.
    Madrid-Gambin F, Pérez-Sáez MJ, Gómez-Gómez A, Haro N, et al · · 2025 · cited 4× · PMID 40008357 · DOI 10.1093/ckj/sfae366

Verify or expand the search:

Other recruiting trials for Frailty

Currently open trials in the same condition.

Other Parc de Salut Mar trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04811417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing